Beri Songna, MD
Nephrology · Nashua, NHNPI 1134412182
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $353 of the $425 with a category attached, or 83.0%. 10 manufacturers reported payments, led by Amgen at 28.6% of the total. 2025 is the largest year on record at $198, 2.4 times the $81 reported in 2021.
Across 15 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$122
- Otsuka America Pharmaceutical, Inc.$56
- Novo Nordisk$49
- Vantive US Healthcare LLC$44
- Novartis$31
- Ardelyx, Inc.$30
- plus $93 from 4 others
What the payments were for
- Food & beverage$35383%
- Education$7217%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 3 | $122 |
| Otsuka America Pharmaceutical, Inc. | 3 | $56 |
| Novo Nordisk | 2 | $49 |
| Vantive US Healthcare LLC | 1 | $44 |
| Novartis | 1 | $31 |
| Ardelyx, Inc. | 1 | $30 |
| Pfizer | 1 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Shield Therapeutics Inc | 1 | $24 |
| Baxter Healthcare | 1 | $19 |
How this compares
$425 in reported general payments places this provider in the 75th percentile of 33 nephrology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $37,667 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $8,454 |
| Sevelamer Carbonate | 15 | $2,406 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,960 |
| Valsartan | 25 | $1,468 |
| Doxazosin Mesylate | 35 | $948 |
| Hydralazine Hcl | 77 | $920 |
| Amlodipine Besylate | 117 | $915 |
| Torsemide | 38 | $856 |
| Allopurinol | 76 | $810 |
| Furosemide | 135 | $771 |
| Tamsulosin Hcl | 35 | $734 |
| Carvedilol | 48 | $544 |
| Bumetanide | 13 | $527 |
| Labetalol Hcl | 11 | $434 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Nashua
- Shaikh HoqueNashua$740
- Siddharth MehtaNashua$589
- Krupa RajurNashua$438
- Sean FitzpatrickNashua$401
- Jill Melendez YoungNashua$106
- Ana StankovicSalem$66K
- Elizabeth BrandtLebanon$41K
- John Patrick SiaManchester$12K
- Sucharit JoshiPortsmouth$6K
- Yishu HanConcord$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.